



# OPTIMAM Database

**Data Licensing Opportunity**  
Clinically linked mammography dataset

---

**FURTHER FASTER TOGETHER**  
We are beating cancer

# Overview

**Indication:** Breast



**Outcome:** Normal to Malignant

**Geography:** UK



**~470,000**

**Clients**



**~7 million**

**Images**



**~1.3 million**

**Studies**

## Data Types

- 2D images
- 3D images
- Clinical
- Pathological
- Ethnicity
- Deprivation

# Background



The OPTIMAM Database (OMI-DB) is a large, centralised & de-identified database of **mammography images** collected from **multiple NHS breast screening sites** across the **UK**

- OMI-DB has been designed to help overcome **the lack of large, curated & representative medical image databases**
- The ongoing collection of images & management of the database is conducted by the **Royal Surrey NHS Foundation Trust** & is funded with support from **Cancer Research UK (CRUK)**
- OMI-DB collects both **processed & unprocessed mammogram images**, associated **clinical, surgical & pathological** data for **all cases**, as well as expert-determined region of interest (**ROI**) **annotations** for a subset of cases
- Where available, follow-up assessment via **3D screening (digital breast tomosynthesis)** assessment & magnetic resonance imaging (MRI) of very high-risk cases is also collected

# Case Description



The database includes both **2D** (FFDM) and **3D** (digital breast tomosynthesis) images

- Majority of cases are 2D: as per UK breast cancer screening guidelines, 3D images are only collected when a case is recalled for further assessment due to a suspicious finding

## 2D

- **4 images** per screening event (2 views of each breast - medio-lateral oblique & cranio-caudal)
- Each case may include images from **multiple screening events**
- **3-year intervals** between screening events

## 3D

- DBT images are typically taken **2-4 weeks** after the initial screening event
- Number of DBT images **varies per case**: some may have 2 views of each breast, the majority are **single breast views**
- Each DBT case will include the **2D images** from **prior screening events** for that client
- DBT images **do not** have expert annotations

# Definitions

## Normal

Cases not classified as malignant or benign, or interval cancer

## Benign

Cases that are classified as **benign** by either surgery, or biopsy, or previously classified as benign

## Malignant

Cases that are classified as **malignant** by either surgery, or biopsy, or previously classified as malignant

## Interval

Symptomatic cases which were **detected & classified as malignant** after a previous screening appointment at which a client received a normal result & **before their next scheduled screening** appointment, or previously classified as interval cancer

## Marked vs. Unmarked

Cases are sub-classified into marked & unmarked, depending on whether **region of interest (ROIs)** have been annotated by an **expert mammography reader**

# Key differentiators



## Large volume

- Imaging & clinical data from **~470,00 clients** across the UK
- **~7 million images** collected via variety of mammography systems



## In-depth clinical data & annotation

- Each case is associated with **detailed clinical information**, including biopsy, clinical, surgery & lesion details
- **Region of interest (ROI) annotations** by expert radiologists are available for a number of cases



## Longitudinal data

- Data collection spans **10+ years** & new mammography images & data are **continually added**
- Information on **previous screening episodes** & **interval cases** are available & can be longitudinally linked



## Standardised & curated

- Data has been **anonymised & standardised** by an expert database management team
- **Bespoke data requests** can be accommodated

# Available data: Summary

**2D images** from ~470,000 cases

Outcome	Number of Cases Available
Normal	424,339
Benign	11,029
Malignant	15,404
Interval Cancers	2,860
Unknown	15,727

**3D images** from ~10,200 cases

Outcome	Number of Cases Available
Normal	4,796
Benign	1,457
Malignant	3,912
Interval Cancers	49

# Available data: Summary

**8,675** marked cases available

<b>Outcome</b>	<b>Number of Cases Available</b>
<b>Benign Marked</b>	1,432
<b>Malignant Marked</b>	7,160
<b>Prior to Interval Cancer Marked</b>	83

# Data Description

## Annotated Images

- **Expert radiologists** at the screening sites retrospectively **identify lesions** on the mammogram images & draw a rectangular ROI around its boundaries representing **ground truth** ( bounding box)
- Coordinates & various properties of the tumour/lesions are recorded & described in the **associated image data**

## Unprocessed Images

- Special arrangements have been made at image collection sites so that **unprocessed images are not discarded**, whereas most PACS systems used in the NHS only store processed images
- **Considerable amounts of unprocessed images** enable research into the fundamental physics of medical imaging

## Associated Clinical Data

- Includes detailed **biopsy, clinical, surgery & lesion** information e.g. invasive status, disease grade, mutation status, screen reader opinion, tumour size, HER2 receptor score etc.
- Please reach out to CRH to request **full details**

## Longitudinal Data

- New mammography images & data are **continually added** to OMI-DB from existing sites & **additional NHS sites** which are being onboarded
- Information on **previous screening episodes & interval cancers** are available within the database & can be longitudinally linked

## Technical & Biological Features

- Cases are recorded & classified with any technical or biological features such as **microcalcifications** or image blurring that can enable further investigation and research
- **Breast density data** (calculated by Volpara Density) may be requested (sharing is subject to further approval)

# Applying for access



## Data access requests

- To access OMI-DB, companies are required to **submit a data access request** to the database team via the [online form](#)
  - The web form will alert the team of your interest & they will send out a more detailed application form to be completed, which will be reviewed by the [OPTIMAM Steering Committee](#)

### Key information required:

- Description of the proposed study & intended use of the data (in both technical & lay terms)
- The specific data types that you would require access to
- Description of the potential patient benefit generated from the use of the dataset



## Licence agreements

Access is subject to a licence agreement with Cancer Research Horizons & Royal Surrey NHS Foundation Trust, which includes terms that align with [CRH's Guiding Principles to Commercial Data Partnerships](#)

### Key terms:

- Data access is offered on a **non-exclusive** basis & solely for the **approved purpose**
- Any **IP** generated from use of the data will be **owned by the company\***
- Licences are **time-limited** (typical term is 3-years)

**Data access** will be facilitated through a Google Cloud Storage Bucket

For licencing inquiries please reach out the CRH team

# Thank you

For further information, please contact:

Jakob Kridl

[jakob.kridl@cancer.org.uk](mailto:jakob.kridl@cancer.org.uk)



---

FURTHER FASTER TOGETHER  
We are beating cancer